NCT03871348 - A First-in-Human Dose Escalation and Expansion Study to Evaluate Intratumoral Administration of SAR441000 as Monotherapy and in Combination With Cemiplimab in Patients With Advanced Solid Tumors | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

January 3, 2019

Primary Completion Date

July 25, 2022

Study Completion Date

February 21, 2024

Conditions

Metastatic Neoplasm

Interventions

DRUG

SAR441000

"Pharmaceutical form: concentrate for solution for injection~Route of administration: intratumoral"

DRUG

Cemiplimab REGN2810

"Pharmaceutical form: solution for injection~Route of administration: intravenous"

Trial Locations (19)

1200

Investigational Site Number : 0560001, Brussels

3000

Investigational Site Number : 0560002, Leuven

9000

Investigational Site Number : 0560003, Ghent

13885

Investigational Site Number : 2500004, Marseille

20246

Investigational Site Number : 2760005, Hamburg

31008

Investigational Site Number : 7240001, Pamplona

44195

Cleveland Clinic - Cleveland- Site Number : 8400007, Cleveland

46014

Investigational Site Number : 7240002, Valencia

55131

Investigational Site Number : 2760001, Mainz

68167

Investigational Site Number : 2760003, Mannheim

69120

Investigational Site Number : 2760004, Heidelberg

72076

Investigational Site Number : 2760006, Tübingen

75010

Investigational Site Number : 2500002, Paris

77030

The University of Texas MD Anderson Cancer Center- Site Number : 8400002, Houston

94805

Investigational Site Number : 2500001, Villejuif

02215

Dana-Farber Cancer Institute- Site Number : 8400003, Boston

6525 GA

Investigational Site Number : 5280002, Nijmegen

3015 CE

Investigational Site Number : 5280001, Rotterdam

08036

Investigational Site Number : 7240004, Barcelona